Suraksha Diagnostic Ltd
Fundamental Score
Suraksha Diagnostic Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of SURAKSHA across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (16.46%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (17.84%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Strong Operating Margins (26.87%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Strong Revenue Growth (17.95%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Strong Profit Growth Track Record (16.38% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Strong Interest Coverage (5.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹102.08 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Strong Institutional Confidence (FII+DII: 35.71%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
5 factors identified
Premium Valuation Risk (P/E: 48.05x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.
Profit Decline Concern (-13.06%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Weak Earnings Growth (-50.98% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
High P/E Ratio
Observation: Stock may be overvalued relative to earnings.
Analysis: P/E above 30 requires strong growth execution to justify current valuations.
Financial Statements
Comprehensive financial data for Suraksha Diagnostic Ltd
About SURAKSHA
Business Overview
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.
Company Details
Key Leadership
SURAKSHA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Suraksha Diagnostic Ltd (SURAKSHA)?
As of 30 Jan 2026, 01:37 pm IST, Suraksha Diagnostic Ltd (SURAKSHA) is currently trading at ₹265.95. The stock has a market capitalization of ₹1.53K (Cr).
Is SURAKSHA share price Overvalued or Undervalued?
SURAKSHA is currently trading at a P/E ratio of 48.05x, compared to the industry average of 39.28x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.
What factors affect the Suraksha Diagnostic Ltd share price?
Key factors influencing SURAKSHA's price include its quarterly earnings growth (Sales Growth: 17.95%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Suraksha Diagnostic Ltd a good stock for long-term investment?
Suraksha Diagnostic Ltd shows a 5-year Profit Growth of 16.38% and an ROE of 16.46%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.51 before investing.
How does Suraksha Diagnostic Ltd compare with its industry peers?
Suraksha Diagnostic Ltd competes with major peers in the Healthcare Service Provider. Investors should compare SURAKSHA's P/E of 48.05x and ROE of 16.46% against the industry averages to determine its competitive standing.
What is the P/E ratio of SURAKSHA and what does it mean?
SURAKSHA has a P/E ratio of 48.05x compared to the industry average of 39.28x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹48 for every ₹1 of annual earnings.
How is SURAKSHA performing according to Bull Run's analysis?
SURAKSHA has a Bull Run fundamental score of 47.1/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does SURAKSHA belong to?
SURAKSHA operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Suraksha Diagnostic Ltd.
What is Return on Equity (ROE) and why is it important for SURAKSHA?
SURAKSHA has an ROE of 16.46%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Suraksha Diagnostic Ltd generates profits from shareholders' equity.
How is SURAKSHA's debt-to-equity ratio and what does it indicate?
SURAKSHA has a debt-to-equity ratio of 0.51, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is SURAKSHA's dividend yield and is it a good dividend stock?
SURAKSHA offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has SURAKSHA grown over the past 5 years?
SURAKSHA has achieved 5-year growth rates of: Sales Growth 9.86%, Profit Growth 16.38%, and EPS Growth -50.98%.
What is the promoter holding in SURAKSHA and why does it matter?
Promoters hold 48.98% of SURAKSHA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is SURAKSHA's market capitalization category?
SURAKSHA has a market capitalization of ₹1534 crores, placing it in the Small-cap category.
How volatile is SURAKSHA stock?
SURAKSHA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for SURAKSHA?
SURAKSHA has a 52-week high of ₹N/A and low of ₹N/A.
What is SURAKSHA's operating profit margin trend?
SURAKSHA has a 5-year average Operating Profit Margin (OPM) of 26.87%, indicating the company's operational efficiency.
How is SURAKSHA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 17.95% and YoY Profit Growth of -13.06%.
What is the institutional holding pattern in SURAKSHA?
SURAKSHA has FII holding of 13.73% and DII holding of 21.98%. Significant institutional holding often suggests professional confidence in the stock.